Background {#Sec1}
==========

Histiocytic sarcoma (HS) is an uncommon malignant neoplasm with morphological and immunophenotypic features of histiocytic tissue. HS presents most commonly with a mass involving soft tissues, gastrointestinal tract, and/or lymph nodes \[[@CR16]\]. Primary histiocytic sarcoma of the central nervous system (CNS) is extremely rare and accounts for less than 1% of all lymphohematopoietic neoplasms \[[@CR22]\]. A typical finding with CNS HS is the presence of an inflammatory infiltrate and the abundance of inflammatory cells can cause neoplastic cells to be overlooked and thus a misdiagnosis may occur \[[@CR2]\]. Many previous cases are thought to be misdiagnosed due to lack of genetic markers, but the disease can now be recognized by its biological markers, such as positive expression of CD 163, CD 68, and lysozyme, which allow differentiation between CNS HS and other hematopoietic neoplasms \[[@CR5]\], such as B-cell or T-cell non-Hodgkin's Lymphoma \[[@CR16], [@CR21]\]. While the optimal treatment for CNS HS is not well defined, surgery is the primary modality with radiotherapy and chemotherapy frequently used as adjuvant treatments. Overall, CNS HS carries a poor prognosis, but there have been reported cases of long term disease free survival in adults when multidisciplinary treatment of radiation therapy, chemotherapy, and surgery are applied \[[@CR2], [@CR11], [@CR23]\]. Here, we present a case of primary CNS HS with leptomeningeal spread treated with tri-modality therapy and provide a review of the available literature for this aggressive disease.

Case presentation {#Sec2}
=================

Our patient was a 47 year old female with a history of ulcerative colitis, Sjogren's syndrome, migraines, and fibromyalgia who presented with a 6 month history of left lower extremity paresthesia followed by a 2 month history of progressive headaches, imbalance, ataxia, nausea, vomiting, and diplopia. Neurologic examination revealed severe gait ataxia requiring assistance to stand or walk and nystagmus with lateral gaze. MRI revealed a 3.0 cm heterogeneously enhancing mixed cystic and solid mass centered upon the cerebellar vermis with mild surrounding vasogenic edema and abnormal thickened enhancement of the bilateral vestibular nerves, left facial nerve, and right trigeminal nerve (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1**a**) Axial T1 Post Gadolinium Fat Saturation. **b**) T2 FLAIR Fat Saturation

The patient was promptly started on steroids, admitted to the hospital, and underwent a midline suboccipital craniotomy for debulking of the large intracerebellar tumor. Upon entering the cystic cavity, grossly purulent material without hemorrhage was noted. Gram stain and cultures were negative for infection. A subtotal resection was achieved and final pathology rendered the diagnosis of primary CNS histiocytic sarcoma (see Fig. [2](#Fig2){ref-type="fig"}). The H&E section (Fig. [2a and b](#Fig2){ref-type="fig"}) revealed sheets of large neoplastic cells with marked cytological atypia, brisk mitosis with occasional multilobated nuclei, and focal necrosis. Extensive immunohistochemical studies (Fig. [2c and d](#Fig2){ref-type="fig"}) showed the neoplastic cells positive for CD163, CD68, CD45, and Vimentin; negative for CD20, CD3, CD30, s-100, CD1a, CD21, CD23, pancytokeratin, MPO, CD61, CD123, GFAP, and BRAF. Further immunostains for PD-L1 with two different antibody clones (22C3 and 28--8) were also performed and showed more than 50% of the tumor cells were positive with membrane stain (Fig. [2e and f](#Fig2){ref-type="fig"}).Fig. 2Final Pathological Examination. The H&E section show the diffuse proliferation of neoplastic histiocytes invading normal brain parenchyma (**a** × 10, upper normal brain; bottom neoplastic histiocytes); the neoplastic histiocytes show marked cytological atypia with brisk mitosis (**b** × 20). Immunohistochemical studies show the histiocytes positive for CD 163 (**c** ×10), CD68 (**d** × 10), CD45 and vimentin; negative for CD20, CD3, CD30, s-100, CD1a, CD21, CD23, pancytokeratin, MPO, CD61, CD123, GFAP, and BRAF. The neoplastic histiocytes are also positive for PD-L1 with both clones (**e**× 10, 22C3 and **f**× 10, 28--8)

Post-operative MRI showed a midline posterior occipital craniotomy with subtotal resection of tumor and continued bilateral-enhancement along multiple cranial nerves, concerning for leptomeningeal spread (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3**a**) Axial T1 Post Gadolinium Fat Saturation. **b**) T2 FLAIR Fat Saturation

A staging PET scan was performed two weeks following surgery suggesting diffuse leptomeningeal spread. A complete spinal MRI confirmed diffuse leptomeningeal spread in the lower thoracic and lumbar spine as well as cauda equina involvement. Due to the convincing evidence on MRI, a CSF analysis was deferred. Standard lab work was within limits, including LDH (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4**a**) Sagittal T2. **b**) Sagittal T1 Post Contrast

Three weeks following surgery, due to progressive lower back pain, she initiated radiation therapy including whole brain radiotherapy (30.6 Gy in 17 fractions) followed by a posterior fossa boost (5.4 Gy in 3 fractions) and a gross tumor boost (9 Gy in 5 fractions), for a total dose of 45 Gy in 25 fractions to gross disease with simultaneous radiation therapy to the lower thoracic and lumbar spine, receiving 40 Gy in 20 fractions, encompassing the areas of leptomeningeal disease in the spine and cauda equina. Full craniospinal radiotherapy was not performed to limit profound cytopenias that may have prevented further cytotoxic chemotherapy.

Interval follow up MRI showed a partial response with persistent posterior fossa disease but near complete resolution of previous leptomeningeal enhancement. Our plan was to initiate chemotherapy with a primary CNS lymphoma regimen with high CNS penetrating therapeutic agents including high-dose methotrexate, high-dose Ara-C, and thiotepa followed by high-dose chemotherapy with BCNU and thiotepa rescued by autologous stem cell transplantation. The patient was started on high dose intravenous methotrexate (HD-MTX) therapy, but received only one cycle secondary to patient intolerance.

A CT of the chest approximately two weeks after initiation of HD-MTX therapy for left sided rib pain showed new pulmonary nodules and a left sided pleural effusion, suspicious for metastatic disease. Thoracentesis revealed findings consistent with a malignant pleural effusion. The patient was initiated on cladribine (Leustatin).

Within two weeks after the completion of this infusion, the patient developed headaches, somnolence, fever, and nuchal rigidity. Malignant meningitis was suspected and the patient was started on IV antibiotics. Lumbar puncture was recommended but the patient declined. Her mental status significantly improved following antibiotic treatment. Brain MRI showed continued response of the cerebellar residual disease and no new intra-cranial lesions, but an MRI of the cervical spine showed new lesions consistent with metastatic disease in the untreated cervical spinal cord and thoracic vertebrae, including intramedullary involvement. She underwent further radiation therapy targeting C4-C6 and T1-T7 (20 Gy in 5 fractions). The patient rapidly showed improvement in symptoms.

Genomic sequencing of her tumor showed a novel mutation in the platelet-derived growth factor receptor A (p.V608I) and therefore, she was started on Dasatinib, a tyrosine kinase inhibitor (TKI) with known CNS penetration \[[@CR24]\]. Unfortunately, this medication was poorly tolerated because of nausea, diarrhea, and acute pancreatitis so it was discontinued after one week.

The patient was readmitted to the hospital for continued decline in functional status, weakness, and failure to thrive. CT images of the chest, abdomen, and pelvis showed progressive bilateral pulmonary nodules. An MRI of the spine showed persistent but significantly improved leptomeningeal enhancement. Due to progression of symptoms, worsening systemic disease despite control of CNS disease, and limited systemic options available, the patient chose to enroll in hospice. The patient expired four weeks later, eight months after initial diagnosis.

Discussion {#Sec3}
==========

Histiocytic sarcoma of the CNS is an uncommon diagnosis with only about 30 total cases reported in the literature. The median age for diagnosis of HS is 46 years, which is equally distributed in males and females \[[@CR20]\]. The prognosis for HS of the CNS is extremely poor with a median survival of 4.5 months, the longest recurrence free period reported being 42 months \[[@CR6], [@CR23]\].

This case was unique and merits discussion for several reasons. First, at the time of surgery, entry into the cerebellar lesion was associated with drainage of purulent material, which has been documented previously in only three other cases \[[@CR1], [@CR3], [@CR26]\]. This was an unexpected finding at the time of surgery and no evidence of infection was identified. Second, this patient had extensive and symptomatic leptomeningeal disease with cranial nerve and spinal involvement by MRI. Leptomeningeal disease is relatively common in CNS HS, 10/31 (32%) documented cases had leptomeningeal involvement, which is associated with a poor quality of life and poor survival. In our case, this disease was treated aggressively with moderate dose radiation therapy, 45 Gy to the gross tumor in the cerebellum and 40 Gy to the leptomeningeal disease in the spine, which did achieve continued disease control, even 6 months after treatment. This raises the question as to whether patients with leptomeningeal spread would benefit from craniospinal radiotherapy. However, full craniospinal radiotherapy can induce profound cytopenias that could limit or delay the use of systemic therapy which has known benefit for histiocytic sarcoma. The other important aspect of this case is that we were able to obtain adequate amount of tissue from surgical resection of the brain tumor and performed genomic sequencing revealing a novel PDGFR mutation which is highly targetable with TKI's. There is very limited literature regarding genomic data in CNS histiocytic sarcoma. One additional case report describes a patient with CNS histiocytic sarcoma with genomic sequencing revealing BRAF V600E mutation. The patient experienced a dramatic clinical and radiographic response with vemurafenib, though the response was not durable and the patient expired 6 months after initiation of treatment \[[@CR17]\]. Our pathologic evaluation showed PD-L1 and PD-L2 expression by the tumor, which suggests that immunotherapy with checkpoint inhibitors should be explored. Using inhibitors to suppress PD-L1/PD-1 interaction has shown promising effects for treatment of various advanced cancers, but no literature is available for HS of the CNS \[[@CR12]\]. Overexpression of PD-1 in an animal model has suggested antitumor immunity may be suppressed in histiocytic sarcoma, although this is yet to be shown in humans \[[@CR27]\]. To the best of our knowledge, our case is the first report of PD-L1/PD-L2 expression in histiocytic sarcoma of the CNS.

A review of the literature for CNS HS was performed and the identified cases are shown in Table [1](#Tab1){ref-type="table"}. Only three of thirty patients (10%) were alive with no evidence of disease at the time of publication, 16, 23, and 42 months after presentation \[[@CR2], [@CR11], [@CR23]\]. Treatment for these cases consisted of surgery followed by concurrent chemoradiation with temozolomide and high dose focal radiation. In the two cases with radiation dose reported, the total dose given was 54 Gy and 61.4 Gy. This is consistent with the findings in our case that moderate doses of radiation are needed for local control.Table 1Reported cases of Primary Histiocytic Sarcoma of the CNS and their characteristicsAuthor & YearAge, GenderSite(s)Number of LesionsSize (cm)Primary TreatmentOutcome^a^Gill-Samra et al. 2012 \[[@CR14]\]38 yr./FTemporalMultiple5Surgery+ WBRT: 45Gy in 25 fractions+ ChemotherapyDOD 3 weeks after presentation^a^Toshkezi et al. 2010 \[[@CR29]\]71 yr./FSpine and leptomeningesSolitary2.5x1x 1.1Surgery+ RT: 44 Gy in 22 fractionsDOD 5 months after presentation^a^Bell et al. 2012 \[[@CR3]\]62 yr./FCerebellumSolitaryNDSurgeryAWPD 24 months^a^Bell et al. 2012 \[[@CR12]\]34 yr./MFrontalSolitary2SurgeryAWPD 10 months^a^ Devic et al., 2012 \[[@CR10]\]43 yr./FCorpus callosum, Cerebellum, and SpineMultipleNDChemotherapyDOD 10 months after presentation^a^Wang et al., 2012 \[[@CR31]\]55 yr./FCorpus callosumMultipleNDSurgery+3D CRT: 16 GyDOD 4 months after presentation^a^Torres et al., 1996 \[[@CR28]\]20 mo/MLeptomeningesSolitaryNDChemotherapyDOD 3 months after presentation^a^ Cheuk et al., 2001 \[[@CR9]\]69 yr./FParietalSolitary1.5Surgery+ WBRT+ ChemotherapyDOD 8 months after presentation^a^ Cheuk et al., 2001 \[[@CR9]\]43 yr./MSpineSolitary1.7Surgery+ WBRT+ ChemotherapyAWPD at 5 months^a^ Cheuk et al., 2001 \[[@CR21]\]11 yr./MCerebellum, occipital, and frontalMultiple.7--1SurgeryDOD 4 months after presentation^a^ Sun et al., 2003 \[[@CR26]\]13 yr./MOccipital and leptomeningesNDND 1.1SurgeryDOD 7 months after presentation^a^Cao et al., 2007 \[[@CR6]\]53 yr./FCavernous sinus, relapsed to mediastinumSolitary3.1 × 2.9 × 2.2Surgery+ RT 54 GyDOD 4 years after presentation^a^Almefty et al., 2013 \[[@CR1]\]16 yr./MParietalSolitary3.5 × 4.4 × 4.0Surgery+ IMRT: 60 Gy in 30 fractionsDOD 4 months after presentation^a^Wu et al., 2013 \[[@CR32]\]50 yr./MParieto-occipitalSolitary1.7Surgery+ SRS: 30 Gy in 5 fractionsAWPD at 18 months^a^ Laviv et al., 2013 \[[@CR19]\]58 yr./MFrontalSolitary6.5SurgeryDOD 4 months after presentation^a^Gomi et al.. 2012 \[[@CR15]\]17 mo/FCerebellum, dissemination to spineSolitary4.7 × 4.3 × 4.3Surgery+ ChemotherapyAWPD at 16 months^a^Gentzler et al., 2011 \[[@CR13]\]52 yr./FParietalSolitary1.7Palliative CareExpired from lung cancer^a^ Perez-Ruiz et al., 2013 \[[@CR23]\]41 yr./FTemporal and leptomeningesSolitary1.5 × 2Surgery+ TMZ + IMRT: 61.2GyANED 42 months^a^Chalasani et al., 2013 \[[@CR7]\]44 yr./MCorpus callosumMultiple3.5 and 2.6Chemotherapy+ WBRT: 26 Gy + Boost to 46 GyDOD 27 weeks after presentation^a^Idbaih et al., 2014 \[[@CR17]\]40 yr./MTemporalSolitaryNDChemotherapyDOD 6 months after presentation^a^Moulinger et al., 2014 \[[@CR22]\]63 yr./FPonsMultipleNDChemotherapyDOD 20 days after completion of treatment^a^ Bai et al., 2014 \[[@CR2]\]52 yr./MFrontalSolitaryNDSurgery+ TMZ + IMRT: 54 GyANED 16 months^a^Foster et al., 2015 \[[@CR11]\]15 yr./FFrontalSolitary5.8 × 4.7 × 4.0Surgery+ TMZ + 3D CRTANED 23 months^a^ Chen et al., 2015 \[[@CR8]\]61 yr./MMeckel's CaveSolitary1.5 × 1.1 × 1.8Radiotherapy 66Gy in 33 fractions + 1 cycle CVP + 2 cycles CHOPAWPD 31 months^a^Brown et al., 2015 \[[@CR4]\]23 yr./MCerebellopontineSolitary6Chemotherapy+ IMRTAWPD 60 months^a^So et al., 2015 \[[@CR25]\]59 yr./MParietal, Corpus callosum, Frontal and SpineMultipleNDChemotherapyDOD 8 months after presentationZanelli et al., 2017 \[[@CR33]\]45 yr./FLeptomeningesN/AN/ANo therapyDOD 2 months after presentation^a^ Ueno et al., 2016 \[[@CR30]\]65 yr./MFrontal, parietal, spine, and leptomeningesMultipleNDRadiotherapyAWPD 11 monthsKim et al., 2017 \[[@CR18]\]16 yr./MCorpus callosum, frontoparietalSolitary6.5 × 5.3Surgery+ Chemotherapy+ Radiotherapy 60GyDOD 12 months after presentationMarguet et al., 2018 \[[@CR21]\]67 yr./MPeriventricular, hypothalamic and sellar region, leptomeningeal involvement.Multiple2.1, 1.4No therapyDOD 7 months after presentationPresent case47 yr/ FCerebellar vermis and leptomeningesMultiple3.0 × 2.9 × 2.3Surgery + WBRT: 30.6 Gy + Boost to 45 Gy + ChemotherapyDOD 8 months after presentation*ANED* Alive and no evidence of disease, *AWPD* Alive with progressive disease, *DOD* Dead of disease, *ND* Not Determined, *PTV* Planning target volume, *WBRT* Whole Brain Radiation Therapy, *3D CRT* 3D Conformal Radiotherapy, *IMRT* Intensity modulated radiotherapy, *TMZ* Temozolomide, *CVP* Cyclophosphamide, vincristine, and prednisone, *CHOP* Cyclophosphamide, doxorubicin, vincristine, and prednisone^a^Indicates patients from manuscript Zanelli et al., 2017 \[[@CR33]\]

The majority of cases in the literature received some form of surgery, radiation, and/or chemotherapy. The current standard treatment for CNS HS is surgery to achieve a maximal safe resection and for tissue diagnosis and relieving cerebral edema. An aggressive, multimodality approach is preferred with postoperative radiation therapy +/− chemotherapy, when the disease is unifocal. When the disease has become multifocal, further aggressive radiotherapy and combination chemotherapy is essential. Chemotherapeutics used previously include temozolomide (TMZ), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), rituximab, ifosfamide, carboplatin, etoposide (ICE), methotrexate, and thalidomide. There are no documented cases in the literature of successful treatment of multifocal disease. Thus, HS is a very aggressive disease when found in the central nervous system which warrants aggressive treatment with multiple modalities. Despite limited long term survivals of this disease, there have been approximately 10% of cases with long term survival with aggressive treatment including surgery, dose escalated radiation therapy, and chemotherapy.

Conclusion {#Sec4}
==========

In this case we present a patient with a primary histiocytic sarcoma of the CNS, an extremely rare diagnosis with a poor prognosis. This patient was treated aggressively with surgery, radiation therapy, chemotherapy, and targeted therapy informed by genomic sequencing but ultimately expired of her progressive disease approximately 8 months after diagnosis. The genomic sequencing of the tumor tissue showed a novel PDGFR mutation, which could be targeted with TKI's. We showed expression of PD-L1 and PD-L2 by the tumor cells suggesting potential therapeutic role for immune checkpoint inhibitors. Our case demonstrates a durable response of CNS disease with radiation doses 40 Gy and above. Therefore, we recommend aggressive treatment with curative radiation doses to the CNS whenever appropriate and possible. Novel therapeutic agents such as TKI's and checkpoint inhibitors need to be explored.
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